secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001619856-25-000014
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring
--------------------------------------------------------------------------------

- Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.
- Cash, equivalents & marketable securities $249.4M at Dec 31, 2024, funding operations into H2 2026.
- CB-010 ANTLER and CB-011 CaMMouflage Phase 1 clinical data expected in H1 2025.
- CSO Steve Kanner to retire end of June 2025; no replacement planned; functions split among execs.
- CFO Sri Ryali appointed in January 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/0001619856-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/crbu-20250310.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer